FDA — authorised 18 September 1992
- Marketing authorisation holder: BAXTER HLTHCARE
- Status: approved
🇺🇸 Suprane in United States
FDA authorised Suprane on 18 September 1992
Marketing authorisations
FDA — authorised 16 December 1997
- Application: NDA020118
- Marketing authorisation holder: BAXTER HLTHCARE
- Indication: Manufacturing (CMC)
- Status: approved
FDA — authorised 26 February 2018
- Application: ANDA208234
- Marketing authorisation holder: SHANGHAI HENGRUI
- Local brand name: DESFLURANE
- Indication: LIQUID — INHALATION
- Status: approved
Suprane in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in United States
Frequently asked questions
Is Suprane approved in United States?
Yes. FDA authorised it on 18 September 1992; FDA authorised it on 16 December 1997; FDA authorised it on 26 February 2018.
Who is the marketing authorisation holder for Suprane in United States?
BAXTER HLTHCARE holds the US marketing authorisation.